Every therapy we offer at DuPage Medical Wellness is supported by peer-reviewed research. This page provides direct links to the key studies underlying our clinical protocols.
Below are the primary outcomes from the pivotal SURMOUNT clinical trials, demonstrating the dual GIP and GLP-1 receptor agonist's efficacy in significant body weight reduction.
In this 72-week double-blind trial, participants taking the 15mg dose achieved an average of 20.9% body weight reduction compared to only 3.1% in the placebo group. Over 50% of the maximum dose group lost 20% or more of their body weight.
Read Full StudyDemonstrated that withdrawing Tirzepatide after a 36-week lead-in period led to weight regain, while participants who continued treatment maintained weight loss or experienced further reductions, emphasizing the need for chronic management.
Read Full StudyData from the monumental STEP trials establishing the GLP-1 receptor agonist as a foundational treatment for chronic weight management and cardiovascular risk reduction.
Over 68 weeks, participants receiving a 2.4 mg subcutaneous dose achieved a mean body weight change of −14.9%, combined with significant improvements in cardiometabolic risk factors compared to lifestyle intervention alone.
Read Full StudyParticipants switching to a placebo after 20 weeks regained significant weight, while those continuing Semaglutide 2.4 mg therapy experienced an additional 7.9% weight loss leading to week 68, proving the efficacy of continuous use.
Read Full StudyShowed a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with overweight or obesity and established cardiovascular disease but without diabetes.
Read Full StudyOur physician is happy to discuss the evidence behind any therapy we offer during your consultation.
Book a ConsultationIn-clinic in Naperville or via telehealth.
Or call us at 630-857-9333
